When a person with a high income decides to pay R$8,000 for a complete diagnostic panel outside of their health plan, this is not a whim. It's a sign that the current model has failed to deliver something she considers essential. Longevity clinics, optimization medicine and premium health coaching services are growing exactly in the space that operators left empty — and this void has the right address: the active management of the health of those who have not yet become ill.
The market that grew without operators noticing
In the United States, the longevity market already generates more than 110 billion dollars a year. Companies like Function Health and Fountain Life have built subscription models that deliver in-depth lab analysis, biomarker tracking, and ongoing expert monitoring — all outside the traditional health insurance loop. In Brazil, the same movement begins to take shape. Clinics focused on advanced preventive medicine, high-resolution imaging exams for cancer screening and executive longevity programs are emerging in capitals such as São Paulo and Rio de Janeiro, with waiting lists and prices that operators simply do not offer.
The point is not that these clinics are luxury. The point is that they reveal what a growing segment of high-value consumers consider essential and that the current model does not deliver. When someone does this in parallel to the plan they already pay for, the message is clear: the plan exists for emergencies, not for health.
Why the current model was not made for longevity
The design of Brazilian health plans is reactive by definition. The operators' contractual, regulatory and economic logic was built to cover events — hospitalizations, surgeries, diagnosed illnesses. This makes sense within a view of health as the absence of disease. The problem is that longevity is something else: it is the active management of biological variables over time, with the aim of compressing morbidity and extending the years of high functional performance.
This distinction is not philosophical. It has direct commercial consequences. When the logic is reactive, the best customer for the operator is the one who pays and doesn't use it. When the logic is one of longevity, the best client is the one who takes preventative care and avoids high-cost events in the future. Operators that still operate according to the first logic are, without realizing it, driving away exactly the customers that it would be most worthwhile to keep.
The customer profile that the sector is missing
The person looking for a longevity clinic has an above-average income, a high level of information about health and a willingness to invest in their own body as a long-term asset. It is also the person who, from an actuarial point of view, tends to use the plan less in the short term and, if well served, generates predictable income for decades. In the life insurance market in developed countries, this profile is called preferred risk — preferential risk, disputed with differentiated rates and personalized products.
In Brazil, this same profile is migrating out of plans. You're not canceling — you're still paying for the plan as a safety net — but you're allocating a significant portion of your healthcare budget to services that the provider simply doesn't offer. The result is a double loss for operators: they lose incremental revenue that they could capture and they lose the relationship of trust that would keep this customer loyal for much longer.
The gap that plans are not seeing
The opportunity is not in copying longevity clinics. It's about recognizing that there is a segment of demand that the current model ignores and building products that address it with regulatory intelligence and scale. Some directions already exist on the global market: premium plans with coverage of advanced screening exams, partnerships with preventive medicine networks, hybrid models with an annual biomarker monitoring subscription included in the monthly fee.
The ANS regulates what plans are required to cover, but does not prevent operators from creating additional layers of value. The space for innovation within regulation exists — what is lacking, in most cases, is the strategic will to occupy it. Operators who first see that longevity is a health product and not a demanding customer's fantasy will come out ahead in the fight for a portfolio that will grow over the next two decades as the Brazilian population ages and the concept of healthspan — years of quality life — becomes popular.
The aging of the Brazilian population is not just a threat to the SUS. It is a change in the preference structure of the private healthcare consumer. And anyone who knows how to read this change as a product opportunity, before reading it just as actuarial pressure, will have found one of the few real organic growth available in a sector that tends towards commoditization.
Also read
- AI in medical diagnosis: what changes in practice for healthcare systems
- Preventive health as a business model: from illness to continuous well-being
- Alternative protein: What food companies need to decide now
- Digital Product Life Cycle: Complete Guide
- Digital Product Life Cycle: Trends and Fundamentals
- The AI Energy Crisis: What Data Center Consumption Means for Infrastructure Decision Makers